The impact of anticholinergics on cognitive function in patients with neurogenic lower urinary tract dysfunction: A narrative review
| Title: | The impact of anticholinergics on cognitive function in patients with neurogenic lower urinary tract dysfunction: A narrative review |
|---|---|
| Authors: | Blayne Welk |
| Source: | Indian Journal of Urology, Vol 40, Iss 2, Pp 82-87 (2024) |
| Publisher Information: | Wolters Kluwer Medknow Publications, 2024. |
| Publication Year: | 2024 |
| Collection: | LCC:Diseases of the genitourinary system. Urology |
| Subject Terms: | Diseases of the genitourinary system. Urology, RC870-923 |
| More Details: | This narrative review discusses the relationship between anticholinergic medications and cognitive change specifically in patients with neurogenic lower urinary tract dysfunction (NLUTD). NLUTD is prevalent in various conditions, including spinal cord injury (SCI), spina bifida (SB), multiple sclerosis (MS), Parkinson’s, stroke, and dementia and often requires anticholinergic overactive bladder (OAB) medications. In the general population, and among those with OAB, several studies have found a significant association between this class of medications and cognitive side effects, mostly when used for > 90 days. These cognitive side effects may be particularly relevant to people with NLUTD due to their higher baseline risk of cognitive impairment. Two studies (one in people with SCI and another in MS) found evidence of cognitive impairment with the use of OAB anticholinergics (specifically oxybutynin and tolterodine). People with dementia commonly use OAB anticholinergics, and there is evidence that oxybutynin and tolterodine may impair cognition in this population. Two recent studies in children with SB studied 12 months of solifenacin and 6 months of fesoterodine/oxybutynin and found there was no significant change in neuropsychological testing. Clinical studies in people with Parkinson’s disease and prior stroke have not shown that trospium, darifenacin, or fesoterodine have a significant impact on cognitive measures. In summary, oxybutynin and tolterodine may pose a higher risk of cognitive impairment than newer OAB anticholinergics in people with NLUTD; there is no evidence that children with SB experience cognitive impairment with OAB anticholinergics. Further study is necessary to confirm cognitive safety, particularly as the NLUTD population may have a high exposure to OAB anticholinergics. Advocating for potentially safer OAB medications is necessary if there is concern about cognitive risks. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 0970-1591 1998-3824 |
| Relation: | https://journals.lww.com/indianjurol/fulltext/2024/04000/the_impact_of_anticholinergics_on_cognitive.3.aspx; https://doaj.org/toc/0970-1591; https://doaj.org/toc/1998-3824 |
| DOI: | 10.4103/iju.iju_352_23 |
| Access URL: | https://doaj.org/article/02046c4aaa164cdfa4e1bd11029b8567 |
| Accession Number: | edsdoj.02046c4aaa164cdfa4e1bd11029b8567 |
| Database: | Directory of Open Access Journals |
| ISSN: | 09701591 19983824 |
|---|---|
| DOI: | 10.4103/iju.iju_352_23 |
| Published in: | Indian Journal of Urology |
| Language: | English |